ID   SLX4I_HUMAN             Reviewed;         408 AA.
AC   Q5VYV7; Q05CG2; Q05CT9;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 1.
DT   07-APR-2021, entry version 111.
DE   RecName: Full=Protein SLX4IP;
DE   AltName: Full=SLX4-interacting protein;
GN   Name=SLX4IP; Synonyms=C20orf94;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [4]
RP   INTERACTION WITH SLX4.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130; SER-213 AND THR-392, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [6]
RP   CHROMOSOMAL REARRANGEMENT.
RX   PubMed=24045615; DOI=10.1093/hmg/ddt447;
RA   Meissner B., Bartram T., Eckert C., Trka J., Panzer-Gruemayer R.,
RA   Hermanova I., Ellinghaus E., Franke A., Moericke A., Schrauder A.,
RA   Teigler-Schlegel A., Doerge P., von Stackelberg A., Basso G., Bartram C.R.,
RA   Kirschner-Schwabe R., Bornhaeuser B., Bourquin J.P., Cazzaniga G.,
RA   Hauer J., Attarbaschi A., Izraeli S., Zaliova M., Cario G., Zimmermann M.,
RA   Avigad S., Sokalska-Duhme M., Metzler M., Schrappe M., Koehler R.,
RA   Te Kronnie G., Stanulla M.;
RT   "Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated
RT   recombination in childhood acute lymphoblastic leukemia.";
RL   Hum. Mol. Genet. 23:590-601(2014).
RN   [7]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-79; LYS-239; LYS-347 AND LYS-356,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [8]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-61; LYS-79; LYS-167; LYS-176;
RP   LYS-239; LYS-242; LYS-256; LYS-291; LYS-347; LYS-356; LYS-372 AND LYS-399,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- SUBUNIT: Interacts with SLX4/BTBD12; subunit of different structure-
CC       specific endonucleases. {ECO:0000269|PubMed:19596235}.
CC   -!- INTERACTION:
CC       Q5VYV7; Q8IY92: SLX4; NbExp=4; IntAct=EBI-2370881, EBI-2370740;
CC   -!- DISEASE: Note=Chromosomal aberrations involving SLX4IP are found in
CC       acute lymphoblastic leukemia. A site-specific deletion within the 5'
CC       region of SLX4IP is found in 30% of childhood acute lymphoblastic
CC       leukemia in general and more than 60% of ETV6/RUNX1-rearranged acute
CC       lymphoblastic leukemia. Breakpoints within SLX4IP reveal junctions with
CC       typical characteristics of illegitimate V(D)J mediated recombination.
CC       SLX4IP deletions are significantly associated with male gender and
CC       ETV6/RUNX1-rearranged acute lymphoblastic leukemia.
CC       {ECO:0000269|PubMed:24045615}.
CC   -!- SIMILARITY: Belongs to the SLX4IP family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20787.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH26094.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL133340; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353599; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL035456; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020787; AAH20787.1; ALT_SEQ; mRNA.
DR   EMBL; BC026094; AAH26094.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS33439.1; -.
DR   RefSeq; NP_001009608.1; NM_001009608.2.
DR   SMR; Q5VYV7; -.
DR   BioGRID; 126147; 46.
DR   IntAct; Q5VYV7; 28.
DR   STRING; 9606.ENSP00000335557; -.
DR   iPTMnet; Q5VYV7; -.
DR   PhosphoSitePlus; Q5VYV7; -.
DR   BioMuta; SLX4IP; -.
DR   DMDM; 74747720; -.
DR   EPD; Q5VYV7; -.
DR   jPOST; Q5VYV7; -.
DR   MassIVE; Q5VYV7; -.
DR   MaxQB; Q5VYV7; -.
DR   PaxDb; Q5VYV7; -.
DR   PeptideAtlas; Q5VYV7; -.
DR   PRIDE; Q5VYV7; -.
DR   ProteomicsDB; 65652; -.
DR   Antibodypedia; 62780; 21 antibodies.
DR   Ensembl; ENST00000334534; ENSP00000335557; ENSG00000149346.
DR   GeneID; 128710; -.
DR   KEGG; hsa:128710; -.
DR   UCSC; uc010zre.3; human.
DR   CTD; 128710; -.
DR   DisGeNET; 128710; -.
DR   GeneCards; SLX4IP; -.
DR   HGNC; HGNC:16225; SLX4IP.
DR   HPA; ENSG00000149346; Low tissue specificity.
DR   MIM; 615958; gene.
DR   neXtProt; NX_Q5VYV7; -.
DR   OpenTargets; ENSG00000149346; -.
DR   PharmGKB; PA25801; -.
DR   VEuPathDB; HostDB:ENSG00000149346.14; -.
DR   eggNOG; ENOG502QQHZ; Eukaryota.
DR   GeneTree; ENSGT00390000016400; -.
DR   HOGENOM; CLU_039900_0_0_1; -.
DR   InParanoid; Q5VYV7; -.
DR   OMA; GIHLRCI; -.
DR   OrthoDB; 575561at2759; -.
DR   PhylomeDB; Q5VYV7; -.
DR   TreeFam; TF330769; -.
DR   PathwayCommons; Q5VYV7; -.
DR   BioGRID-ORCS; 128710; 6 hits in 994 CRISPR screens.
DR   ChiTaRS; SLX4IP; human.
DR   GenomeRNAi; 128710; -.
DR   Pharos; Q5VYV7; Tdark.
DR   PRO; PR:Q5VYV7; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q5VYV7; protein.
DR   Bgee; ENSG00000149346; Expressed in metanephros and 208 other tissues.
DR   ExpressionAtlas; Q5VYV7; baseline and differential.
DR   Genevisible; Q5VYV7; HS.
DR   InterPro; IPR031479; SLX4IP.
DR   PANTHER; PTHR28557; PTHR28557; 1.
DR   Pfam; PF15744; UPF0492; 1.
PE   1: Evidence at protein level;
KW   Isopeptide bond; Phosphoprotein; Reference proteome; Ubl conjugation.
FT   CHAIN           1..408
FT                   /note="Protein SLX4IP"
FT                   /id="PRO_0000306119"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         213
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         392
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        61
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        79
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        167
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        176
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        239
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        242
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        256
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        291
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        347
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        356
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        372
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        399
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         317
FT                   /note="R -> Q (in dbSNP:rs6077853)"
FT                   /id="VAR_035277"
SQ   SEQUENCE   408 AA;  45552 MW;  4CBC9DF90E3B14E9 CRC64;
     MASKKFAVKC GNFAVLVDLH ILPQGSNKDT SWFSEQKKEE VCLLLKETID SRVQEYLEVR
     KQHRPSNAEF TRSNPLSLKG YGFQITAYFL KRGIRLRCIR STQNAELCVF PDRFVVCVSQ
     LAFSRDLLAS QNEDLTERVL HGVSDYFAEC AESSLPPSAK LRRNALKEIV KRTETKSSVT
     SKSQTRRDTV ETSSDSVIAE IARRRNDGQA SSSPPSESMG QAKDSIKAAE SHWGLPVQKL
     EKVNQTQPED TSGQQKPHPG ERLKTGLLSR SPVCSCESAS PCPKQSPRVA KTQQKRRNCS
     SAEDFDHHGR VSLGSDRLVP REIIVEKSKA VRVLPASELS DPGLLLKQDL AKTTSKEELH
     VLESLSSRHL MKNNPGQAQQ TGLATNTERL STIQNSPTKK RKKYERGH
//
